



Contact:

David Waldman or Justyna Gudaszewska

Crescendo Communications, LLC

Email: mmd@crescendo-ir.com

Tel: +48 693 354 580

Pugliese Ciaccio First Hospital in Italy to Adopt Milestone Medical's CompuFlo® Instrument

Real-time, objective tool for accurate epidural space identification boosts provider confidence

LIVINGSTON, NJ, February 4, 2019 – Milestone Medical Inc. (WAR: MMD) today announced Ospedale “Pugliese Ciaccio” di Catanzaro is the first hospital in Italy to use the CompuFlo® Epidural System (“CompuFlo”) for all epidurals in labor and delivery. For a local hospital performing a limited number of epidurals, CompuFlo offers a real-time, objective tool for accurate epidural space identification to help reduce failure rates and accidental dural punctures that can require further treatment and interventions.

CompuFlo features an innovative Dynamic Pressure Sensing technology® that differentiates tissue types by pressure signatures at the tip of the needle that are imperceptible by touch. Anesthesia providers at Pugliese Ciaccio continue to trust the sensitive, tactile feel of their technique, but gain greater confidence with the objective numerical, graphical and auditory verification from CompuFlo that they have accessed the epidural space.

[A recent study in the top ranked Anesthesia & Analgesia Journal](#) found CompuFlo to be ninety-nine percent successful in objectively identifying the epidural space—even in challenging patients with a higher body mass index. CompuFlo's procedure time was reported to be the same as loss of resistance technique. The data from this pivotal study confirms that CompuFlo is a safe and highly effective alternative to current standards of care.

Pino Purrone of PF Medical, a CompuFlo distributor in the Calabria region, commented, “Pugliese Ciaccio's new standard of care with the CompuFlo Epidural Instrument is good for both providers and patients. We anticipate more hospitals will follow suit as CompuFlo provides a measure of safety not available to medical professionals using conventional syringes that rely on subjective perception to identify the epidural space.”

Luca Lombardo, Sales Manager Critical Care at Movi SPA, who assisted in the sale commented, “We are impressed with Milestone Medical's CompuFlo Epidural System following several extensive trials in Italy including Pugliese Ciaccio. We see an unmet need with anesthesiologists for a disruptive technology that delivers more accurate epidural placement. Providers are recognizing that CompuFlo offers a standard of care that can objectively boost confidence and reduce complications.”

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2017. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

#